Compare Merck & Co., Inc. (MRK) vs United States Natural Gas Fund (UNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs United States Natural Gas Fund — how do they compare? Merck & Co., Inc. trades at $142.44 (market cap $351.28B), while United States Natural Gas Fund trades at $10.79 (market cap $517.27M). The key difference: Merck & Co., Inc. is far larger — about 679.1× United States Natural Gas Fund's market cap, and Merck & Co., Inc. pays a 2.39% dividend while United States Natural Gas Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and United States Natural Gas Fund for 22 Days on average.
| MRK | UNG | |
|---|---|---|
Market Cap | $351.28B | $517.27M |
Volume | 7,969,665 | 29,485,537 |
Sector | Health | Commodities - Energy |
52-Week High | $156.43 | $16.90 |
52-Week Low | $82.49 | $9.63 |
Typical Hold Time | 98 Days | 22 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
UNG trades at $11.03, up 2.7% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported a net income of $65.15 million in 2024 with no revenue, while cash flow from operations was positive at $47.54 million. Recent news highlights natural gas price volatility driven by record U.S. production and geopolitical tensions in the Middle East.
The outlook is mixed: strong profitability and low debt support fundamentals, but zero revenue and negative net cash flow pose risks. Geopolitical events and weather-dependent demand create volatility, making the stock sensitive to energy market shifts. Analyst sentiment is cautiously optimistic given the bullish technical setup.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About United States Natural Gas Fund
UNG is a commodity ETF that tracks the daily price movements of natural gas futures. It primarily invests in front-month contracts at the Henry Hub, making it a highly volatile tool for short-term trading rather than long-term holding due to contango and roll costs.
Read more on UNG →
